• Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

  • Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

  • Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

  • Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response

 

MISSION Therapeutics is a private drug discovery company focused on elucidating and targeting the ubiquitin pathway to treat cancers and other diseases. The company is developing small molecule drugs that target deubiquitylating enzymes (DUBs) involved in the DNA damage response, with the aim of inducing synthetic lethality, a powerful mechanism to selectively kill specific tumour cells. Our novel DUB technology platform integrates unique biology, screening and chemistry capabilities to rapidly and effectively select and develop compounds targeting DUBs.

To deliver highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response.